Bard Associates’s Pfizer PFE Stock Holding History

Bard Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.7K	Hold	650	–	–	﹤0.01%	210
2026 Q1	$18.3K	Buy	650 +350	+117%	+$9.32K	﹤0.01%	191
2025 Q4	$7.47K	Buy	+300	New	+$7.57K	﹤0.01%	215

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bard Associates's PFE Position: Q2 2026 in Review

Bard Associates held its Pfizer (PFE) position steady in Q2 2026 at 650 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #210.

Bard Associates first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $18.3K in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Bard Associates held 650 shares of Pfizer worth $15.7K as of Q2 2026.
Bard Associates left its Pfizer share count unchanged in Q2 2026.
Pfizer made up ﹤0.01% of Bard Associates's portfolio in Q2 2026, its #210 holding.
Bard Associates first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
Bard Associates's Pfizer position peaked at $18.3K in Q1 2026.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.